Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.69 |
| ▸ | CFD | P00746 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606673 | 0.91 | EPHX2 (0.68) | HDAC6HDAC2HDAC8CFDPPARG | |
| SCHEMBL4161846 | 0.90 | HDAC6 (0.60) | HDAC6HDAC2HDAC8CFDALDH1A1 | |
| SCHEMBL11900328 | 0.88 | HDAC6 (0.87) | HDAC6HDAC2HDAC8CFDALDH1A1 | |
| SCHEMBL7607244 | 0.87 | PTGS1 (0.60) | HDAC6HDAC2HDAC8CFDPPARG | |
| SCHEMBL9999560 | 0.87 | HDAC6 (0.60) | HDAC6HDAC2HDAC8CFDALDH1A1 | |
| SCHEMBL22047184 | 0.85 | PPARG (0.78) | HDAC6HDAC2HDAC8CFDALDH1A1 | |
| SCHEMBL1023993 | 0.84 | SENP1 (0.58) | HDAC6HDAC2HDAC8CFDALDH1A1 | |
| SCHEMBL16598155 | 0.84 | HDAC6 (0.66) | HDAC6HDAC2HDAC8CFDALDH1A1 | |
| SCHEMBL1319399 | 0.83 | NR1H4 (0.68) | HDAC6HDAC2HDAC8CFDALDH1A1 | |
| SCHEMBL7610793 | 0.83 | CA1 (0.56) | CFDALDH1A1KDM1AHTTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161360-A | Tricyclic heterocyclic derivative and preparation method and application thereof | 浙江省人民医院 | 2024-12-20 | — | — | CN | disclosed |
| US-20230045031-A1 | Diarylamide Compound and Application Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-3984534-A1 | DIARYLAMIDE COMPOUND AND APPLICATION THEREOF | Peking University (CN) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020253802-A1 | DIARYLAMIDE COMPOUND AND APPLICATION THEREOF | 北京大学 | 2020-12-24 | — | — | WO | disclosed |
| CN-101906053-B | Amide derivatives | MITSU CHEMICALS INC | 2012-11-21 | — | — | CN | disclosed |
| CN-1310169-A | Anils with nitric oxide synzyme inhibiting function | SHUGAI SEIYAKU K K (JP) | 2001-08-29 | — | — | CN | disclosed |
| US-5998399-A | Guanidine derivatives useful in therapy as inhibitors of nitric oxide synthetase | ASTRA AKTIEBOLAG (SE) | 1999-12-07 | — | — | US | disclosed |
| EP-0690851-B1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AB (SE) | 1999-05-19 | — | — | EP | disclosed |
| US-5885985-A | Guanidine derivatives useful in therapy | ASTRA AKTIEBOLAG (SE) | 1999-03-23 | — | — | US | disclosed |
| CN-1172473-A | Aniline derivatives having nitric oxide synthase inhibitory activity | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0690851-A1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | Astra Aktiebolag (SE) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021621-A1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045031-A1 | Diarylamide Compound and Application Thereof | SLC14A1, SLC28A1, SLC28A2 | HDAC6 946/4885HDAC2 2039/4885HDAC8 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.